Skip to main content
Erschienen in: Journal of Interventional Cardiac Electrophysiology 3/2022

11.03.2022 | Commentary

Left atrial appendage closure in patients with intracranial hemorrhage: the clock is ticking — to take the bull by the horn or wait for a randomized controlled trial

Editorial commentary regarding “Left atrial appendage closure in patients with intracranial hemorrhage” by Garg and colleagues

verfasst von: Alberto Alfie, Patrick Müller

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Excerpt

One of the primary goals of atrial fibrillation (AF) management is the prevention of thromboembolic events and balance the risk of bleeding events due to oral anticoagulation (OAC) therapy. Intracranial hemorrhage (ICH) is a challenging clinical scenario in AF management, because there is lack of evidence of randomized controlled trials (RCT) for determining the best clinical strategy to prevent further thromboembolic and bleeding occurrence. This high-risk population was not included in the landmark RCT (PROTECT AF, PREVAIL) due to the need of long-term OAC therapy. These RCTs were designed to compare the safety and efficacy of left atrial appendage occlusion (LAAO) versus long-term oral anticoagulation (OAC) with warfarin for stroke prevention in non-valvular AF [1, 2]. …
Literatur
2.
Zurück zum Zitat Holmes Jr DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the Warchman left appendage closure device in patients with atrial fibrillation versus long-term waerfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;8:64(1):1–12. https://doi.org/10.1016/j.jacc.2014.04.029. Holmes Jr DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the Warchman left appendage closure device in patients with atrial fibrillation versus long-term waerfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;8:64(1):1–12. https://​doi.​org/​10.​1016/​j.​jacc.​2014.​04.​029.
4.
Zurück zum Zitat Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of ESC. Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.CrossRef Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of ESC. Eur Heart J. 2021;42(5):373–498. https://​doi.​org/​10.​1093/​eurheartj/​ehaa612.CrossRef
6.
Zurück zum Zitat Reddy VY, Möbius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with Watchman device in patients with contraindication for oral anticoagulation: the ASAP study ( ASA Plavix feasibility study with Watchman left atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61(25):2551–6. https://doi.org/10.1016/j.jacc.2013.03.035.CrossRef Reddy VY, Möbius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with Watchman device in patients with contraindication for oral anticoagulation: the ASAP study ( ASA Plavix feasibility study with Watchman left atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61(25):2551–6. https://​doi.​org/​10.​1016/​j.​jacc.​2013.​03.​035.CrossRef
7.
Zurück zum Zitat Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, et al. Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology: final 2-year outcome data of EWOLUTION trial focusing in history of stroke and hemorrhage. Circ Arrhythm Electrophysiol. 2019;12(4):e006841. https://doi.org/10.1161/CIRCEP.118.006841.CrossRef Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, et al. Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology: final 2-year outcome data of EWOLUTION trial focusing in history of stroke and hemorrhage. Circ Arrhythm Electrophysiol. 2019;12(4):e006841. https://​doi.​org/​10.​1161/​CIRCEP.​118.​006841.CrossRef
9.
11.
Zurück zum Zitat Karolinska University Hospital. Prevention of stroke by left atrial appendage closure in atrial fibrillation patients after intracerebral hemorrhage. (clinicaltrial.gov NCT02830152) Karolinska University Hospital. Prevention of stroke by left atrial appendage closure in atrial fibrillation patients after intracerebral hemorrhage. (clinicaltrial.gov NCT02830152)
Metadaten
Titel
Left atrial appendage closure in patients with intracranial hemorrhage: the clock is ticking — to take the bull by the horn or wait for a randomized controlled trial
Editorial commentary regarding “Left atrial appendage closure in patients with intracranial hemorrhage” by Garg and colleagues
verfasst von
Alberto Alfie
Patrick Müller
Publikationsdatum
11.03.2022
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 3/2022
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-022-01180-6

Weitere Artikel der Ausgabe 3/2022

Journal of Interventional Cardiac Electrophysiology 3/2022 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.